Sungening

Sungening Bio is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of next-generation gene therapies. The company utilizes a proprietary adeno-associated virus (AAV) platform to design treatments for a variety of high-need areas, including ophthalmology, metabolic disorders, and the central nervous system. Its lead program, SG-001, is an AAV-delivered gene therapy currently in clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Sungening aims to transform the treatment landscape by providing durable, single-administration therapies that eliminate the need for frequent intravitreal injections. The company is backed by prominent investors such as IDG Capital and GL Ventures, supporting its mission to advance genetic medicine.